RainDance Technologies is a technology company.
RainDance Technologies has raised $58.0M across 2 funding rounds.
Key people at RainDance Technologies.
RainDance Technologies has raised $58.0M in total across 2 funding rounds.
Key people at RainDance Technologies.
RainDance Technologies has raised $58.0M in total across 2 funding rounds.
RainDance Technologies's investors include TCV, Wildcat Ventures, Joanna Rees.
RainDance Technologies was a life sciences company founded in 2004 that developed droplet-based microfluidic technologies, including the RainDrop Digital PCR System and RainStorm digital droplet technology, to enable more accurate, reliable, cost-effective, and early detection of cancer, inherited diseases, and predisposition risks.[1][2][3] These products powered next-generation sequencing (NGS), genetic testing, targeted DNA sequencing, and applications like low-frequency tumor allele detection, gene expression analysis, copy number variation, and single-cell analysis, serving major academic research institutions, clinical genetics labs, hospitals, and biotech researchers worldwide.[1][2][3] The company raised $146.65M before being acquired by Bio-Rad on January 16, 2017, marking the end of its independent operations.[1]
Headquartered in Billerica, Massachusetts (with some references to Lexington), RainDance focused on simplifying complex genetics through ultra-sensitive tools like picodroplet PCR, which generated over a billion reactions daily for superior sensitivity, quantitation, and multiplexing.[1][2][3] Its systems were compatible with major NGS platforms (e.g., Illumina HiSeq, Ion Torrent PGM) and emphasized high-throughput (up to 96 samples per run), low cost per sample, and uniform sequence coverage, driving better healthcare outcomes and cost reductions in research, diagnosis, and treatment.[3]
RainDance Technologies was founded in 2004 in Massachusetts, pioneering digital biology through innovative droplet-based PCR and microfluidic solutions for human health and disease research.[1][3][4] The founders leveraged expertise in microfluidics to create the RainStorm and RainDrop platforms, addressing limitations in traditional PCR by enabling picodroplet technology for unprecedented sensitivity and precision in genetic analysis.[2][3] Early traction came from delivering systems like the RDT 1000 sequence enrichment solution to institutions such as the J. Craig Venter Institute (JCVI), establishing reliability in research settings.[4] The company evolved from general genomic tools to specialized applications in cancer detection, liquid biopsies, and NGS, building a global network of distributors before its 2017 acquisition by Bio-Rad.[1][2]
RainDance stood out in the genomics space through these key strengths:
RainDance rode the early 2010s boom in next-generation sequencing and precision medicine, capitalizing on demand for non-invasive liquid biopsies and digital PCR to detect cancer and genetic diseases earlier amid falling sequencing costs.[1][2][5] Its timing aligned with market forces like rising cancer prevalence, personalized healthcare shifts, and NGS adoption in clinics, enabling tools that improved sensitivity over analog methods and influenced standards in research institutions globally.[3][4] By powering ground-breaking applications in somatic mutation analysis, medical genetics, and single-cell work, RainDance contributed to the ecosystem's evolution toward affordable, high-precision diagnostics, paving the way for post-acquisition advancements under Bio-Rad.[1]
Post-2017 acquisition by Bio-Rad, RainDance's technologies have likely integrated into broader life sciences portfolios, enhancing Bio-Rad's droplet digital PCR offerings for ongoing innovation in oncology and genetics.[1] Trends like multiomics, AI-driven analysis, and expanded liquid biopsies will shape their legacy, amplifying early detection capabilities amid growing global demand for precision medicine. As genomics scales, RainDance's foundational tools continue influencing cost-effective disease screening, underscoring its enduring role in transforming human healthcare from a standalone pioneer to an embedded ecosystem driver.[2][3]
RainDance Technologies has raised $58.0M across 2 funding rounds. Most recently, it raised $20.0M Series E in April 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2013 | $20.0M Series E | TCV, Wildcat Ventures, Joanna Rees | |
| Jan 1, 2011 | $38.0M Series D | TCV, Wildcat Ventures, Joanna Rees |
